Clinical trials for inflammatory bowel disease: Global guidance during the covid-19 pandemic

behalf of the International Organization for the Study of Inflammatory Bowel Diseases [IOIBD]

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


The severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]-causing coronavirus disease [COVID]-19 pandemic poses major challenges for patients with inflammatory bowel disease [IBD] to be recruited and maintained in clinical trials. However, clinical trials offer patients who have failed multiple drugs access to study medications with alternative modes of action and the potential for relief from inflammation-mediated symptoms. Therefore, the continuation of clinical trials in IBD during the COVID-19 pandemic is important both for participants and for the community of IBD patients, due to the dire need for an expanded therapeutic armamentarium. As the safety of patients in clinical trials is the leading principle, we are providing ten specific rules to guide patients and principal investigators safely through the challenging time.

Original languageEnglish (US)
Pages (from-to)S815-S819
JournalJournal of Crohn's and Colitis
StatePublished - Oct 1 2020


  • COVID-19
  • Clinical trials
  • Crohn's disease
  • Inflammatory bowel disease
  • SARS-CoV2
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Clinical trials for inflammatory bowel disease: Global guidance during the covid-19 pandemic'. Together they form a unique fingerprint.

Cite this